|
OKANO Teruo
Department Research Institutes and Facilities, Research Institutes and Facilities Position |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera |
| Journal | Formal name：Molecular therapy. Methods & clinical development Abbreviation：Mol Ther Methods Clin Dev ISSN code：(2329-0501)2329-0501(Linking) |
| Volume, Issue, Page | 2,pp.14066 |
| Author and coauthor | Watanabe Natsumi†, Yano Kazuo, Tsuyuki Kenichiro, Okano Teruo, Yamato Masayuki* |
| Publication date | 2015/02 |
| Summary | The first commercially approved human gene therapy in the Western world is Glybera (alipogene tiparvovec), which is an adenoassociated viral vector encoding the lipoprotein lipase gene. Glybera was recommended for marketing authorization by the European Medicines Agency in 2012. The European Medicines Agency had only ever reviewed three marketing authorization applications for gene therapy medicinal products. Unlike in the case of Glybera, the applications of the first two products, Cerepro and Contusugene Ladenovec Gendux/Advexin, both of which were for cancer diseases, were withdrawn. In this report, we studied the European public assessment reports of the three gene therapy products. During the assessment process, Glybera was re-examined and reviewed for a fourth time. We therefore researched the re-examination procedure of the European Union regulatory process. Approximately 25% of the new medicinal products initially given negative opinions from the Committee for Medicinal Products for Human Use were ultimately approved after re-examination from 2009 to 2013. The indications of most medicines were changed during the re-examination procedure, and the products were later approved with a mode of approval. These results suggested that the re-examination system in the European Union contributed to the approval of both several new drugs and the first gene therapy product. |
| DOI | 10.1038/mtm.2014.66 |
| PMID | 26052534 |